Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference
An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime slee...
Gespeichert in:
Veröffentlicht in: | Sleep medicine reviews 2023-02, Vol.67, p.101714-101714, Article 101714 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 101714 |
---|---|
container_issue | |
container_start_page | 101714 |
container_title | Sleep medicine reviews |
container_volume | 67 |
creator | Khoshnevis, Sepideh Smolensky, Michael H. Haghayegh, Shahab Castriotta, Richard J. Hermida, Ramon C. Diller, Kenneth R. |
description | An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects. |
doi_str_mv | 10.1016/j.smrv.2022.101714 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2754047249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1087079222001277</els_id><sourcerecordid>2754047249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</originalsourceid><addsrcrecordid>eNp9kMtqHDEQRYVJ8PsHsghaZtNjPVuj4M0wiR9giDHxWqilaluTVvdY0th4E_wb_r18ibsZJ8usqijOvVAHoU-UzCih9clqlmN6nDHC2HRQVOygfSo5q5iW8sO4k7mqiNJsDx3kvCKEaEHrXbTHa0k0YXof_b4BN8QIvQePS4ihv8NDiyP44GwJQ59xubcFh7i2ruDcAayx7T1-sr-g3XQ95PwVL3CCxwBPU7TcA15ESGO-x9cJskuhgZT_vLzib-EuFNvhG2ghQe_gCH1sbZfh-H0eotuz7z-XF9XVj_PL5eKqclzWpeItV_NWzWsNUlBq_ZwB1axuama9Vk4IZz1V3LaultxKrqR2VvBGW0p5o_gh-rLtXafhYQO5mBiyg66zPQybbJiSggjFhB5RtkVdGnJO0Jp1CtGmZ0OJmbyblZm8m8m72XofQ5_f-zfN6O5f5K_oETjdAjB-OapKJrswGfAhgSvGD-F__W-iKJYT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754047249</pqid></control><display><type>article</type><title>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Khoshnevis, Sepideh ; Smolensky, Michael H. ; Haghayegh, Shahab ; Castriotta, Richard J. ; Hermida, Ramon C. ; Diller, Kenneth R.</creator><creatorcontrib>Khoshnevis, Sepideh ; Smolensky, Michael H. ; Haghayegh, Shahab ; Castriotta, Richard J. ; Hermida, Ramon C. ; Diller, Kenneth R.</creatorcontrib><description>An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects.</description><identifier>ISSN: 1087-0792</identifier><identifier>EISSN: 1532-2955</identifier><identifier>DOI: 10.1016/j.smrv.2022.101714</identifier><identifier>PMID: 36509029</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Administration time ; American Prescribers' Digital Reference ; Antidepressive Agents ; Humans ; Medications ; Melatonin - therapeutic use ; Norepinephrine - pharmacology ; Sleep - physiology ; Sleep promotion and disturbance ; Wakefulness - physiology ; Wakefulness promotion and disturbance</subject><ispartof>Sleep medicine reviews, 2023-02, Vol.67, p.101714-101714, Article 101714</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</citedby><cites>FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1087079222001277$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36509029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khoshnevis, Sepideh</creatorcontrib><creatorcontrib>Smolensky, Michael H.</creatorcontrib><creatorcontrib>Haghayegh, Shahab</creatorcontrib><creatorcontrib>Castriotta, Richard J.</creatorcontrib><creatorcontrib>Hermida, Ramon C.</creatorcontrib><creatorcontrib>Diller, Kenneth R.</creatorcontrib><title>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</title><title>Sleep medicine reviews</title><addtitle>Sleep Med Rev</addtitle><description>An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects.</description><subject>Administration time</subject><subject>American Prescribers' Digital Reference</subject><subject>Antidepressive Agents</subject><subject>Humans</subject><subject>Medications</subject><subject>Melatonin - therapeutic use</subject><subject>Norepinephrine - pharmacology</subject><subject>Sleep - physiology</subject><subject>Sleep promotion and disturbance</subject><subject>Wakefulness - physiology</subject><subject>Wakefulness promotion and disturbance</subject><issn>1087-0792</issn><issn>1532-2955</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtqHDEQRYVJ8PsHsghaZtNjPVuj4M0wiR9giDHxWqilaluTVvdY0th4E_wb_r18ibsZJ8usqijOvVAHoU-UzCih9clqlmN6nDHC2HRQVOygfSo5q5iW8sO4k7mqiNJsDx3kvCKEaEHrXbTHa0k0YXof_b4BN8QIvQePS4ihv8NDiyP44GwJQ59xubcFh7i2ruDcAayx7T1-sr-g3XQ95PwVL3CCxwBPU7TcA15ESGO-x9cJskuhgZT_vLzib-EuFNvhG2ghQe_gCH1sbZfh-H0eotuz7z-XF9XVj_PL5eKqclzWpeItV_NWzWsNUlBq_ZwB1axuama9Vk4IZz1V3LaultxKrqR2VvBGW0p5o_gh-rLtXafhYQO5mBiyg66zPQybbJiSggjFhB5RtkVdGnJO0Jp1CtGmZ0OJmbyblZm8m8m72XofQ5_f-zfN6O5f5K_oETjdAjB-OapKJrswGfAhgSvGD-F__W-iKJYT</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Khoshnevis, Sepideh</creator><creator>Smolensky, Michael H.</creator><creator>Haghayegh, Shahab</creator><creator>Castriotta, Richard J.</creator><creator>Hermida, Ramon C.</creator><creator>Diller, Kenneth R.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202302</creationdate><title>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</title><author>Khoshnevis, Sepideh ; Smolensky, Michael H. ; Haghayegh, Shahab ; Castriotta, Richard J. ; Hermida, Ramon C. ; Diller, Kenneth R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-3f378f7869e5411ad82e1926b62ad97c44cad173afc653a53759ca43b9a113b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Administration time</topic><topic>American Prescribers' Digital Reference</topic><topic>Antidepressive Agents</topic><topic>Humans</topic><topic>Medications</topic><topic>Melatonin - therapeutic use</topic><topic>Norepinephrine - pharmacology</topic><topic>Sleep - physiology</topic><topic>Sleep promotion and disturbance</topic><topic>Wakefulness - physiology</topic><topic>Wakefulness promotion and disturbance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khoshnevis, Sepideh</creatorcontrib><creatorcontrib>Smolensky, Michael H.</creatorcontrib><creatorcontrib>Haghayegh, Shahab</creatorcontrib><creatorcontrib>Castriotta, Richard J.</creatorcontrib><creatorcontrib>Hermida, Ramon C.</creatorcontrib><creatorcontrib>Diller, Kenneth R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Sleep medicine reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khoshnevis, Sepideh</au><au>Smolensky, Michael H.</au><au>Haghayegh, Shahab</au><au>Castriotta, Richard J.</au><au>Hermida, Ramon C.</au><au>Diller, Kenneth R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference</atitle><jtitle>Sleep medicine reviews</jtitle><addtitle>Sleep Med Rev</addtitle><date>2023-02</date><risdate>2023</risdate><volume>67</volume><spage>101714</spage><epage>101714</epage><pages>101714-101714</pages><artnum>101714</artnum><issn>1087-0792</issn><eissn>1532-2955</eissn><abstract>An appreciable number of medicines have a recommended unique single time-of-day or asymmetrical or unequal-interval multiple-daily administration schedule. Many prescription and over-the-counter (OTC) products, according to administration time, can exert positive or negative impact on nighttime sleep and daytime wakefulness. Intuitively, medicines used to manage nighttime sleep and daytime wake disorders should be taken, respectively, at night before bedtime and morning after arising. However, some utilized for other medical conditions, if improperly timed, may compromise nocturnal sleep and diurnal attentiveness. We conducted a comprehensive review of the American Prescribers' Digital Reference, internet version of the Physician's Desk Reference, for the recommended scheduling of medications and OTC remedies that can impact sleep and wakefulness. The search revealed several hundred therapies of various classes -- α2-receptor agonists, antidepressants, barbiturates, central nervous system stimulants, benzodiazepines, dopamine agonists, dopamine norepinephrine reuptake inhibitors, selective norepinephrine reuptake inhibitors, eugeroics, γ-aminobutyric acid modulators, H1 and H3-receptor antagonists, melatonin analogues, OTC melatonin-containing products, non-benzodiazepine benzodiazepine-receptor agonists, dual orexin-receptor antagonists, and serotonin modulators -- that have a recommended unique dosing schedule. The tables and text of this article are intended to guide the proper scheduling of these medicines to optimize desired and/or minimize undesired effects.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36509029</pmid><doi>10.1016/j.smrv.2022.101714</doi><tpages>1</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1087-0792 |
ispartof | Sleep medicine reviews, 2023-02, Vol.67, p.101714-101714, Article 101714 |
issn | 1087-0792 1532-2955 |
language | eng |
recordid | cdi_proquest_miscellaneous_2754047249 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Administration time American Prescribers' Digital Reference Antidepressive Agents Humans Medications Melatonin - therapeutic use Norepinephrine - pharmacology Sleep - physiology Sleep promotion and disturbance Wakefulness - physiology Wakefulness promotion and disturbance |
title | Recommended timing of medications that impact sleep and wakefulness: A review of the American Prescribers’ Digital Reference |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A55%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recommended%20timing%20of%20medications%20that%20impact%20sleep%20and%20wakefulness:%20A%20review%20of%20the%20American%20Prescribers%E2%80%99%20Digital%20Reference&rft.jtitle=Sleep%20medicine%20reviews&rft.au=Khoshnevis,%20Sepideh&rft.date=2023-02&rft.volume=67&rft.spage=101714&rft.epage=101714&rft.pages=101714-101714&rft.artnum=101714&rft.issn=1087-0792&rft.eissn=1532-2955&rft_id=info:doi/10.1016/j.smrv.2022.101714&rft_dat=%3Cproquest_cross%3E2754047249%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754047249&rft_id=info:pmid/36509029&rft_els_id=S1087079222001277&rfr_iscdi=true |